| Infliximab (remicade) and increased incidence of development of Basal cell carcinoma. | |
| | |
MedLine Citation:
|
PMID: 22527438 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Immunosuppression is a known risk factor for the development of non-melanoma skin cancers (NMSC). Certain medications that induce immunosuppression, such as tumor necrosis factor-? (TNF-?) inhibitors, are being used more frequently. We report a case of a young, pregnant woman who was treated with infliximab for Crohn's disease, and subsequently experienced a rapid growth of two pre-existing basal cell carcinomas. As use of TNF-? inhibitors increases, it is important to closely monitor patients for the development of NMSC. J Drugs Dermatol. 2012;11(5):655-656. |
| | |
Authors:
|
Elizabeth Gaines-Cardone; Elizabeth K Hale |
Related Documents
:
|
22525818 - Angiotensin ii type i receptor and mir-155 in endometrial cancers: synergistic antiprol... 22550058 - Plasmacytoid urothelial carcinoma-diagnostic challenge in cytology. 22523628 - Photodynamic therapy for breast cancer in a balb/c mouse model. 16890648 - Second primary malignancies associated with renal cell carcinoma histological subtypes. 7333778 - The prevention and management of lymphoedema after treatment for breast cancer. 7262368 - The determinants of breast-feeding in sri lanka. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of drugs in dermatology : JDD Volume: 11 ISSN: 1545-9616 ISO Abbreviation: J Drugs Dermatol Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-04-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160020 Medline TA: J Drugs Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 655-6 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A new simple, safe, and easy solution for upper lip dermabrasion.
Next Document: Treatment of mild to moderate facial melasma with the lumixyl topical brightening system.